| scholarly article | Q13442814 |
| P50 | author | Michael A. Carducci | Q114718060 |
| P2093 | author name string | Mario A Eisenberger | |
| Jenny J Kim | |||
| Raanan Berger | |||
| Avishay Sella | |||
| Daniel Keizman | |||
| Avivit Peer | |||
| Maya Gottfried | |||
| Natalie Maimon | |||
| Victoria Sinibaldi | |||
| Wilmosh Mermershtain | |||
| Raya Leibowitz-Amit | |||
| Keren Rouvinov | |||
| Rony Weitzen | |||
| P2860 | cites work | Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. | Q51800636 |
| Clinical trial participation and outcome for patients with glioblastoma: multivariate analysis from a comprehensive dataset. | Q55461673 | ||
| Clinical research in epithelial ovarian cancer and patients' outcome | Q82265696 | ||
| Is there a positive effect of participation on a clinical trial for patients with advanced non-small cell lung cancer? | Q83105059 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study | Q33510317 | ||
| Does enrollment in cancer trials improve survival? | Q33895814 | ||
| Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". | Q33935724 | ||
| Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib | Q34916352 | ||
| New insights into the biology of renal cell carcinoma | Q35180400 | ||
| Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination | Q35219246 | ||
| The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. | Q35542896 | ||
| Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review | Q35642930 | ||
| The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma | Q36353298 | ||
| Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials | Q37160677 | ||
| Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib | Q37519031 | ||
| Comparison of survival outcomes among cancer patients treated in and out of clinical trials | Q37696455 | ||
| No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia | Q39896075 | ||
| Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma | Q40138029 | ||
| The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. | Q41830553 | ||
| New tools for assessing the individual risk of metastasis in renal cell carcinoma. | Q44540214 | ||
| Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma | Q46248263 | ||
| Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma | Q46416422 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | metastatic renal cell carcinoma | Q19000948 |
| P304 | page(s) | 281-287 | |
| P577 | publication date | 2015-03-05 | |
| P1433 | published in | Cancer Research and Treatment | Q18411021 |
| P1476 | title | Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? | |
| P478 | volume | 48 |
| Q33437427 | Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. |
| Q36525418 | Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma |
| Q40490003 | Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region |
| Q38823987 | Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma. |
| Q89947341 | Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases |
Search more.